

## **FAST FACTS**

- 1. Clinical validation of treatment from government-led study**
- 2. Patient-centric benefits of equal efficacy, faster onset, increased discretion confirmed**
- 3. First commercial application of Pasture's innovative drug delivery platform**

### **Pasture Holdings' Innovative Drug Delivery System Demonstrates Clinical Success in Independent Government Study**

16/05/25

Pasture Holdings Ltd (SGX:UUK) is proud to share the results of a major clinical study validating its Oral Disintegrating Strip (ODS) technology—part of an innovative drug delivery system designed to enhance patient care through faster onset, greater convenience, and more discreet medication delivery.

The trial evaluated HART-S, Pasture's proprietary sildenafil ODS formulation. HART-S, a treatment for erectile dysfunction (ED), is the first commercial application of Pasture's novel ODS platform. The study was independently conducted by Thailand's Government Pharmaceutical Organization (GPO), operating under the Thai Ministry of Public Health, ensuring objectivity and regulatory oversight.

Conducted over two years beginning in 2018, the prospective, randomised trial, enrolled 120 patients and compared HART-S (sildenafil 50mg) to conventional sildenafil tablets. Published in 2021 by Elsevier Inc. on behalf of the International Society for Sexual Medicine, the findings clinically validated that HART-S is equally effective and safe as traditional tablets, with the added benefits of a faster onset of action, enhanced discretion, and improved ease of use—factors that may significantly improve patient adherence and satisfaction.



“This milestone is not just a win for Pasture—it’s a win for patient-centric innovation,” said Lloyd Soong, Executive Chairman and CEO of Pasture Holdings. “Our Oral Disintegrating Strips represent a shift toward more thoughtful drug delivery systems—ones that acknowledge how people want to live, not just how medicine is traditionally made.”

### **What makes Pasture’s ODS technology different**

Pasture’s ODS is part of its broader innovation in drug delivery systems designed for real-world usability. The strip dissolves rapidly in the mouth without the need for water, making it ideal for individuals who dislike swallowing pills, prefer discreet usage, or have dietary or mobility restrictions that interfere with pill absorption.

### **Timing is everything**

While the trial was published in 2021, Pasture waited to share these results until there was a tangible business path to further invest in and scale the technology. “The timing had to be right. We were not yet in a position to fully capitalize on this opportunity,” said Mr. Soong. “Now, as we expand into new verticals and geographies, we are ready to bring this innovation to the forefront of our future strategy.”

This successful trial reinforces Pasture’s position as a lean but innovative “small pharma” player that prioritizes practical, people-first health solutions. As the company evolves and scales its offerings across human and animal health, its ODS platform opens new doors in the treatment of conditions where flexibility, rapid onset, and patient comfort are essential.

Pasture’s R&D division, housed under their Pacific Biosciences Pte. Ltd subsidiary, continues to explore applications for the platform across a range of therapeutic categories.

To read the full study, visit: <https://doi.org/10.1016/j.esxm.2021.100453>

#### **Media Inquiries**

2 Corporation Rd, #03-04/05  
Singapore 618494

[contact@pasturegroup.com](mailto:contact@pasturegroup.com)

[+65 6515 6516](tel:+6565156516)